NHLBI Training Program in Pharmacoepidemiology

NHLBI 药物流行病学培训计划

基本信息

批准号：
10329925
负责人：
G. Caleb Alexander
金额：
$ 21.25万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-01-01 至 2024-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10329925
关键词：
National Heart, Lung, and Blood Institute Pharmacoepidemiology Training Programs

项目摘要

PROJECT SUMMARY / ABSTRACT Pharmacoepidemiology is a bridge science that uses tools from pharmacology, epidemiology and clinical medicine to understand the use, safety and effectiveness of drugs in large populations. The need for experts in this field has never been greater. During the past decade, dozens of new therapies have been brought to market, including products made from living cells, or biologics, to address common and costly heart, lung and blood conditions ranging from homozygous familial hypercholesterolemia to idiopathic pulmonary fibrosis to Hemophilia A. With the rise in access to promising yet expensive drugs comes the need to study their benefits and risks in diverse populations as well as to understand best use of these medicines to improve human health. In addition, many of pharmacoepidemiology's tools and methods are also highly relevant to the study of use, safety and effectiveness of other medical products including diagnostics, devices, and drug-device combinations. We propose a training program in pharmacoepidemiology for pre- and post-doctoral trainees at the Johns Hopkins Bloomberg School of Public Health and Johns Hopkins School of Medicine. These institutions are exceptionally well suited to this task. The Bloomberg School of Public Health is the oldest and largest School of Public Health in the world, having celebrated its centennial this year, while the Johns Hopkins School of Medicine is an internationally renowned leader in scientific research and clinical medicine. Our proposed program will leverage a wealth of human capital and material resources at Johns Hopkins to provide comprehensive, longitudinal, and integrated training and professional development opportunities to future leaders in the field. We will use this award to train scientists who will identify and address fundamental questions about the use, safety and effectiveness of medicines and other medical products for the treatment of heart, lung and blood diseases. Given the strengths of our faculty and trainee pool, we will also support the development of innovative methods to do so. Thus, our trainees will develop skills to generate evidence that can be used to address the needs of patients, clinicians, payers, regulators and other stakeholders, and in so doing, improve the optimal use of medicines to treat heart, lung and blood diseases in the United States.

项目概要/摘要药物流行病学是一门桥梁科学，它使用药理学、流行病学和临床工具了解药物在大量人群中的使用、安全性和有效性。需要以下领域的专家这个领域从未如此之大。在过去的十年中，数十种新疗法被引入市场，包括由活细胞或生物制品制成的产品，以解决常见且昂贵的心脏、肺和血液疾病范围从纯合子家族性高胆固醇血症到特发性肺纤维化 A 型血友病。随着有希望但昂贵的药物的普及，需要研究它们的益处和不同人群的风险，以及了解这些药物的最佳用途，以改善人类健康健康。此外，药物流行病学的许多工具和方法也与药物流行病学的研究高度相关。其他医疗产品（包括诊断、设备和药物设备）的使用、安全性和有效性组合。我们为博士前和博士后学员提出了药物流行病学培训计划约翰·霍普金斯大学彭博公共卫生学院和约翰·霍普金斯大学医学院。这些机构非常适合这项任务。布隆伯格公共卫生学院是历史最悠久、规模最大的世界上最大的公共卫生学院，今年庆祝了百年华诞，而约翰·霍普金斯大学医学院在科学研究和临床医学方面处于国际知名的领先地位。我们的拟议的计划将利用约翰霍普金斯大学丰富的人力资本和物质资源来提供面向未来的全面、纵向、综合培训和专业发展机会该领域的领导者。我们将利用这个奖项来培训能够识别和解决基本问题的科学家有关治疗疾病的药物和其他医疗产品的使用、安全性和有效性的问题心脏、肺和血液疾病。鉴于我们的教师和实习生库的优势，我们还将支持开发创新方法来做到这一点。因此，我们的学员将培养技能来生成证据可用于满足患者、临床医生、付款人、监管机构和其他利益相关者的需求，从而这样做，改善美国治疗心脏、肺和血液疾病的药物的最佳使用。

项目成果

期刊论文数量（25）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Noninterventional studies in the COVID-19 era: methodological considerations for study design and analysis.

COVID-19 时代的非干预性研究：研究设计和分析的方法学考虑。

DOI：
发表时间：
2023-01
期刊：
影响因子：
7.2
作者：
Butler, Anne M;Burcu, Mehmet;Christian, Jennifer B;Tian, Fang;Andersen, Kathleen M;Blumentals, William A;Joynt Maddox, Karen E;Alexander, G Caleb
通讯作者：
Alexander, G Caleb

Risk of Major Bleeding Associated with Concomitant Direct-Acting Oral Anticoagulant and Clopidogrel Use: A Retrospective Cohort Study.

与同时使用直接作用口服抗凝剂和氯吡格雷相关的大出血风险：一项回顾性队列研究。

DOI：
发表时间：
2024-03
期刊：
影响因子：
4.2
作者：
Hwang, Y Joseph;Chang, Hsien;Metkus, Thomas;Andersen, Kathleen M;Singh, Sonal;Alexander, G Caleb;Mehta, Hemalkumar B
通讯作者：
Mehta, Hemalkumar B

Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.

二肽基肽酶 4 抑制剂的心血管安全信号：高危患者中的不成比例分析。

DOI：
发表时间：
2018
期刊：
影响因子：
2.6
作者：
Baksh, Sheriza N;McAdams;Segal, Jodi B;Alexander, G Caleb
通讯作者：
Alexander, G Caleb

Comparative Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin Among Adults With Cancer and Atrial Fibrillation.

直接口服抗凝剂与华法林在成人癌症和心房颤动患者中的有效性和安全性比较。

DOI：
发表时间：
2022-12
期刊：
影响因子：
0
作者：
Mehta, Hemalkumar B;An, Huijun;Ardeshirrouhanifard, Shirin;Raji, Mukaila A;Alexander, G Caleb;Segal, Jodi B
通讯作者：
Segal, Jodi B

Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative.

长期使用免疫抑制药物和院内 COVID-19 结果：一项使用国家 COVID 队列合作组织数据的回顾性队列研究。

DOI：
发表时间：
2022-01
期刊：
影响因子：
0
作者：
Andersen, Kathleen M;Bates, Benjamin A;Rashidi, Emaan S;Olex, Amy L;Mannon, Roslyn B;Patel, Rena C;Singh, Jasvinder;Sun, Jing;Auwaerter, Paul G;Ng, Derek K;Segal, Jodi B;Garibaldi, Brian T;Mehta, Hemalkumar B;Alexander, G Caleb;National COVI
通讯作者：
National COVI